trending Market Intelligence /marketintelligence/en/news-insights/trending/fvBjYY8RXb0UB55ahVkytQ2 content esgSubNav
In This List

Pfizer prices cash tender offer of €2B notes due 2021

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer prices cash tender offer of €2B notes due 2021

Pfizer Inc. priced its tender offer to buy back its outstanding €2 billion 5.750% notes due 2021.

The cash offer price is €1,208.34, with a yield of -0.285%, payable in cash per each €1,000 principal amount of the 2021 notes. The cash offer includes €30 of consent payment as part of the solicitation of consents by the company to shorten the redemption period of the notes.

The company said as of 5 p.m. ET Dec. 20, €834 million, or about 41.7%, of the principal amount of the outstanding 2021 notes were bought back.

Pfizer said the tender offer will expire at 11:59 p.m. ET on Jan. 5, 2018, and the final settlement date is expected by Jan. 10, 2018.